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The advent of nanomedicine has recently started to innovate the
treatment of cardiovascular diseases, in particular myocardial
infarction. Although current approaches are very promising, there
is still an urgent need for advanced targeting strategies. In this
work, the exploitation of macrophage recruitment is proposed as a
novel and synergistic approach to improve the addressability of the
infarcted myocardium achieved by current peptide-based heart
targeting strategies. For this purpose, an acetalated dextran-based
nanosystem is designed and successfully functionalized with two
diﬀerent peptides, atrial natriuretic peptide (ANP) and linTT1,
which target, respectively, cardiac cells and macrophages associ-
ated with atherosclerotic plaques. The biocompatibility of the
nanocarrier is screened on both macrophage cell lines and primary
macrophages, showing high safety, in particular after functionali-
zation of the nanoparticles’ surface. Furthermore, the system
shows higher association versus uptake ratio towards M2-like
macrophages (approximately 2-fold and 6-fold increase in murine
and human primary M2-like macrophages, respectively, compared
to M1-like). Overall, the results demonstrate that the nanosystem
has potential to exploit the “hitchhike” eﬀect on M2-like
macrophages and potentially improve, in a dual targeting strategy,
the ability of the ANP peptide to target infarcted heart.
1. Introduction
Cardiovascular diseases (CVDs), and in particular, myocardial
infarction (MI), are a global burden, causing 17.8 million
deaths in 2017.1 The high mortality associated with CVDs is
due to the inability of the human adult heart to replace the
loss of cardiomyocytes (up to one billion may be lost in a MI)2
and restore the cardiac function.3 Fibrosis is taking
place instead, leading to a chronic lethal syndrome, called
heart failure (HF).4 Unfortunately, current therapies are still
unsuccessful, because they are mainly aimed at managing
symptoms of the disease, but unable to change the fate of
cardiomyocytes.
The advent of nanomedicine has brought new insights in
innovative treatment strategies, currently at the pre-clinical
stage, of CVD, in particular MI.5–10 Such approaches are very
promising, but there is urgent need for smart targeting strat-
egies. The infarcted tissue is challenging to address due to
mechanical obstacles, like the constant pumping of the organ
and the restless massive exchange of blood.11 Recently,
Ferreira et al.,12 investigated the in vivo targeting abilities of
diﬀerent heart targeting peptides, demonstrating that atrial
natriuretic peptide (ANP) is a peptide that allows nanoparticles
to accumulate in the infarcted heart. However, ANP lacks the
targeting exclusiveness towards cardiac tissue, because its
receptors are expressed not only in the heart, but also in the
kidneys, lungs, brain, testes, adipose tissue, adrenal gland
tissues and vascular smooth muscle cells.13 Herein, we intro-
duce an alternative strategy to improve the heart targeting pro-
perties of ANP. Considering the conspicuous involvement of
inflammation during infarction, we explore the macrophage
recruitment in order to “hitchhike” on macrophages and
increase the ANP-functionalized nanoparticle accumulation in
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the infarcted heart. It is known that promptly after MI, neutro-
phils are recruited to the infarcted tissue, creating an oxidative
stress milieu and producing a variety of inflammatory cyto-
kines, which will further recruit on-site diﬀerent populations
of monocytes and macrophages.14,15 This monocyte/macro-
phage enrolment can be divided into two sequential phases. A
first phase, which peaks at day 3 after the onset of MI, sees an
accumulation of inflammatory type Ly-6Chigh monocytes/M1-
type macrophages, which phagocytose dead cells and debris to
make space for the evolving scar. Six days after the infarction
onset, a second phase, characterized by the presence of
healing Ly-6Cint/low monocytes/M2-type macrophages, super-
venes and promotes the repair of the tissue with the release of
the vascular endothelial growth factor (VEGF) and transform-
ing growth factor beta (TGFβ), which support angiogenesis
and collagen production, leading to the formation of un-func-
tional scar tissue.14,15
Cellular hitchhiking is a very well-known approach used in
the nanomedicine field.16 In the past, researchers exploited
the long circulating properties of red blood cells,17,18 macro-
phages/monocytes19–22 and other cells23,24 to increase the cir-
culation time17 and targeting abilities of specific nano-
carriers,18 and avoid the rapid clearance of diagnostic and
imaging agents.22 With this aim, we designed a putrescine-
modified acetalated dextran (Putre-AcDEX)-based nanosystem,
functionalized with ANP and TT1 peptides.
Acetalated dextran (AcDEX) was chosen because it is easy
to modify and is highly biocompatible both as a starting
material and in terms of degradation products,25 and due to
its pH-responsiveness.26,27 The polymer was modified with
putrescine to provide functional groups for further surface
conjugations and to reduce the toxicity towards primary car-
diomyocytes observed with spermine-modified nano-
particles.5 Spermine particles are highly positively charged
even after the conjugations, due to free amine groups
present in the structure. The system was loaded with two
small hydrophobic compounds, CHIR99021 and SB203580,
which have shown a synergistic eﬀect in stimulating cardio-
myocyte proliferation.28
To endow nanoparticles with heart targeting ability, the
surface of the nanocarrier was modified with ANP and TT1
peptides, attached to the nanoparticles’ surface through a
branched polyethylene glycol (PEG). Linear TT1 (Lin-TT1)
(AKRGARSTA) is a well-established peptide for its tumor-
homing abilities.29–31 The peptide addresses tumors by
binding to the mitochondrial chaperone protein p32, normally
expressed at the intracellular level, but translocated on the
surface of tumor cells, tumor associated macrophages, tumor
endothelial cells, as well as on macrophages associated with
atherosclerotic plaques.30,32,33 The TT1 peptide, similar to
integrin-binding arginine–glycine–aspartic acid (iRGD) and
LyP-1 peptides, contains a cryptic basic sequence motif (C-end
Rule or CendR motif ), that is, following cell surface recruit-
ment of the peptide by the p32-dependent mechanism, proteo-
lytically processed to activate the CendR element and allow
interaction of the peptide with the secondary receptor neutro-
pilin-1 (NRP-1).34 This interaction initiates an uptake process
similar to classical endocytosis.34
The aim of this work is to evaluate the successful conju-
gation of both peptide moieties on the nanoparticles’ surface,
assessing the biocompatibility of the nanosystem and studying
its interactions with both continuous macrophage cell lines
and primary M1- and M2-like macrophages. For this purpose,
we have tested the viability and uptake of both macrophage
cell lines and primary macrophages treated with diﬀerent con-
centrations of the nanosystem.
2. Results and discussion
2.1. Characterization of Putre-AcDEX nanoparticles
Putre-AcDEX nanoparticles were prepared by an oil-in-water
(o/w) single emulsion method.35 The two hydrophobic com-
pounds, CHIR99021 and SB203580 (abbreviated as C and S,
respectively) were dissolved together with the polymer in the
organic phase. Then, an aqueous solution of polyvinyl alcohol
(PVA), which functions as a stabilizer, was added and the emul-
sion was created with the help of high energy sonication.
Upon evaporation of the organic solvent for 3 h, the nano-
particles formed entrapped the compounds in a matrix-like
structure. The surface of the nanoparticles was then functiona-
lized with PEG and the two peptides, linTT1 and ANP, in order
to achieve dual targeting. After preparation, the nanoparticles
were characterized by dynamic light scattering (DLS) and elec-
trophoretic light scattering (ELS) to obtain information about
their size, polydispersity index (PDI), and zeta (ζ)-potential
(Fig. 1A).
The nanoparticles were characterized by an increase of size
after diﬀerent conjugation steps. In particular, empty nano-
systems showed a significant increase in hydrodynamic dia-
meter after functionalization with the two peptides. Loaded
particles did not show such a size increase, suggesting a stabi-
lizing eﬀect of the loaded compounds, C and S.
The PDI varied accordingly, showing higher values for
empty particles after conjugation with linTT1 and ANP pep-
tides, which are characteristic of heterogeneous nanoparticle
suspensions,36 supporting the stabilizing theory of the loaded
compounds. The charge of the nanoparticles was also
measured, suggesting that the diﬀerent components were
eﬀectively conjugated on the surface of the nanoparticles. The
bare nanosystem had a high positive charge (ca. +40 mV), due
to the presence of amine groups from putrescine. After
PEGylation, the ζ-potential dropped to negative values
(−30 mV), due to the presence of carboxyl-terminated groups
in the PEG. The conjugation of the linTT1 peptide, reversed
the charge to slightly positive values (ca. +10 mV), and this can
be explained due to the presence of arginine residues in the
peptide sequence. The charge had a further small increase of
ca. 10 mV (reaching values of +20 mV) after conjugation of the
ANP peptide, which is rich in positively charged arginine resi-
dues, and thus, responsible for the increase of the positive
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charge. The presence of PEG was furthermore confirmed by
KBr-Fourier transform infrared (FTIR) spectroscopy (Fig. 1B).
The presence of the amide-indicative bands at
1565–1570 cm−1 (in-plane N–H bending and C–N stretching)
and 1630–1640 cm−1 (amide CvO stretching) confirmed the
formation of a covalent amide bond between the Putre-AcDEX
and PEG, and the appearance of a shoulder at 1735 cm−1
(CvO stretching from –COOH belonging to PEG and male-
imide groups), underlined by the yellow band in Fig. 1B,
denotes the presence of free carboxyl groups.
The conjugation of linTT1 and ANP peptides did not
change the FTIR spectrum, thus further methods were used to
confirm the successful conjugation of the peptides onto the
nanoparticle’s surface. The presence of linTT1 was detectable
due to its conjugation with carboxyfluorescein (FAM), which
imparted fluorescence to the nanoparticles after conjugation
with the peptide. Moreover, we performed a binding assay to
ensure that the peptide was conjugated with the correct orien-
tation, and thus, kept its functionality. The assay consisted of
coating Ni-NTA magnetic agarose beads with the recombinant
hexahistidine-tagged target of the linTT1 peptide, p32.37 Then,
beads were incubated with FAM-labeled nanoparticles conju-
gated with the linTT1peptide or without it. Beads were finally
washed and the nanoparticle-p32 complexes were released
using imidazole elution buﬀer and the eluted fluorescence was
measured. As shown in Fig. 1C, the eluted fractions collected
from beads incubated with Putre-PEG-TT1-ANP nanoparticles,
presented a significantly higher fluorescence compared to
those collected from beads that interacted with particles
without the peptide. This demonstrates that the functionally
active linTT1 peptide was conjugated onto the nanoparticles’
surface. The eﬀective conjugation of ANP was further con-
firmed by elemental analysis, which showed the presence of
about 14.14 µg of ANP in 1 mg of Putre-PEG-TT1-ANP nano-
particles (Table S2†).
The nanoparticles’ morphology was obtained through
transmission electron microscopy (TEM) (Fig. 1D), and the
images showed round-shaped nanoparticles, with a diameter
comprised between 100 and 200 nm, a bit smaller than what
was observed with DLS. This phenomenon is in accordance
with the fact that DLS measures the hydrodynamic diameter of
the particles, whereas TEM refers to dry particles.38
2.2. Release studies and pH-dependent behavior
The release profile of the two encapsulated drug compounds,
C and S, was evaluated in phosphate buﬀer saline (PBS) (pH
7.4) and acetate (pH 5.0) buﬀers, in order to mimic the physio-
logical extracellular environment and the conditions found in
acidic intracellular compartments after internalization in the
cells, respectively.39 In addition, the determination of the drug
loading degree (LD) and encapsulation eﬃciency (EE) values of
bare and functionalized particles was also conducted as shown
in Table S3.†
The encapsulation of the drug molecules was done at a
molar ratio C : S of 1 : 2, which is the optimal ratio, according
to the literature, in order to induce cardiomyocyte
proliferation.40,41 Upon functionalization, there is a loss of
encapsulated drugs, because some of the compounds might
still be on the surface of the nanoparticles, even though they
were washed thoroughly. Another reason could be that the
system is saturated due to the high amount of compounds
loaded at the beginning of the preparation process.
However, the amount of encapsulated drugs was still
enough to produce an eﬀect on cells.42,43
As previously demonstrated,44–46 AcDEX-based nano-
particles should release drugs faster at acidic pH, because of
the pH-dependent hydrolysis of acetal groups present in
AcDEX. The results obtained are in accordance with what was
previously reported, as shown in Fig. 2.
At pH 5.0 both the drugs were released faster compared to
pH 7.4 (Fig. 2C and D). Free drugs were used as controls and
especially in the case of C, nanoparticles increased their dis-
solution rate in aqueous media. Also, the solubility of C was
aﬀected by pH, where the free drug was more soluble at pH 5.0
than at pH 7.4. For S at pH 5.0, it can be noted that the nano-
particles prevented drug degradation, because the free drug
started degrading after 8 h, whereas the drug-loaded nano-
particles showed a release of the drug concentration up to
24 h. Moreover, the nanosystem conjugated with PEG and the
Fig. 1 Physicochemical characterization of Putre-AcDEX nanoparticles.
(A) Average size, PDI, and ζ-potential before and after the diﬀerent con-
jugation steps. Letters E and L are used to diﬀerentiate between empty
and loaded particles, respectively. The bare system is named Putre;
PEGylated nanoparticles are abbreviated as PEG; particles conjugated
with only TT1 peptide are named TT1, and the system after conjugation
with all the peptides is called ANP. (B) KBr-FTIR spectra of the bare and
functionalized nanoparticles. (C) TT1 binding assay. Fluorescent labelled
nanoparticles conjugated with both ANP and TT1 peptides (Putre-
PEG-TT1-ANP) were compared with PEGylated particles made ﬂuor-
escent after conjugation with 6-carboxyﬂuorescein (Putre-PEG-FAM).
(D) TEM images of the bare nanoparticles and after surface functionali-
zation. Values are represented as the mean ± standard deviation (s.d.) (n
≥ 3 biological replicates in which each time 3 technical replicates have
been used). The data were analysed by two-way ANOVA followed by a
Tukey–Kramer post hoc test, using GraphPad Prism 7 software.
Statistical signiﬁcance was set at probabilities of *p < 0.05, **p < 0.01,
and ***p < 0.001.
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peptides (named CS@Putre-AcDEX-PEG-TT1-ANP in the plot),
presented a faster drug release of the drugs compared to the
bare nanoparticles (named CS@Putre-AcDEX in the plot). This
can be explained by the increased hydrophilicity of the nano-
system after surface modifications, which can promote the
interaction with the solvent molecules and allow the release of
the drugs entrapped in the polymer matrix close to the surface
of the nanoparticles.47–49
Even though the drug release was faster at pH 5.0, there was
a small amount of drugs released already at pH 7.4, which is
justifiable by a slight degradation of AcDEX at this pH, as pre-
viously reported.5,50 This loss of drugs at pH 7.4 can also
justify the decrease of the LD and EE values of the nano-
particles after the various conjugation steps. After PEGylation,
washings were performed in a solution of 2% of sucrose at pH
7.4, in order to prevent the degradation of the maleimide
groups of PEG needed to interact with the thiol groups of the
TT1 peptide. Overall, these AcDEX-based nanoparticles were
successfully designed to release payloads mostly in the acidic
subcellular compartments of the cells, which can be con-
sidered optimal for intravenous administration. Furthermore,
it is known that inflammation occurring in the ischemic myo-
cardium lowers the interstitial pH to 6–6.5, which makes the
AcDEX-based nanoparticles a valuable candidate for the sus-
tained release of cargos in the infarcted heart.26,27
2.3. Cytocompatibility
The cytocompatibility of the developed nanosystem was
assessed on macrophage cell lines, RAW 264.7 and KG-1, as
well as on primary macrophages, of both human and murine
origins. Cells were incubated with the nanoparticles for 24 and
48 h, since the drugs are released in 24 h and also because the
desired eﬀect on cardiomyocytes, produced by the compounds
C and S (stimulation of cardiomyocyte proliferation by re-entry
of cardiomyocytes in the cell cycle), takes time to manifest. At
each time point, cell viability was assessed by CellTiter-Glo®
luminescence assay.51 As shown in Fig. 3, both bare nano-
particles and Putre-AcDEX-PEG-TT1-ANP, empty and loaded,
were safe towards RAW 264.7 and KG-1 cell lines.
Empty bare nanoparticles were slightly toxic at higher con-
centrations, probably due to the presence of putrescine, which
endows the nanosystems with a high positive charge. Positively
charged nanoparticles are toxic towards cells, because of the
high interaction between the cationic surface groups of the
nanoparticles and the negatively charged cell membranes,
which cause disruption of the plasma-membrane integrity,
production of a high number of autophagosomes and damage
to cellular organelles, in particular mitochondria and lyso-
somes.52 After surface functionalization, the charge of the
nanosystems is not highly positive anymore, thus the toxicity
is reduced and the nanoparticles are more likely biocompati-
ble. Moreover, the encapsulation of drugs corresponded to a
significant increase in cell viability, suggesting a protective
eﬀect of the two compounds.53–55 Researchers demonstrated
that the inhibition of p38 MAPK53 and activation of canonical
wnt signaling55 pathways are implicated not only in the cyto-
kine production of stimulated macrophages, but also in their
proliferation. SB203580, a p38 MAPK inhibitor, promotes
macrophage proliferation by increasing the stability of gra-
Fig. 2 Release proﬁles of drug-loaded Putre-AcDEX nanoparticles.
Release proﬁles of CHIR99021 (A and C) and SB203580 (B and D) from
bare CS@Putre-AcDEX and functionalized CS@Putre-AcDEX-PEG-TT1-
ANP at pH 7.4 and 5.0, at 37 °C. Data represented as mean ± s.d. (n ≥ 3
biological replicates in which each time 3 technical replicates have been
used).
Fig. 3 Cell viability of macrophage cell lines. Cytocompatibility studies
were conducted to assess the safety of the produced nanoparticles on
both RAW 264.7 (A–B) and KG-1 (C–D) cell lines. Values are represented
as mean ± s.d. (n = 3 biological replicates in which each time 3 technical
replicates have been used). A one-way ANOVA followed by a Tukey–
Kramer post hoc test was used for the statistical analysis. The signiﬁ-
cance levels of the diﬀerences were set at probabilities of *p < 0.05, **p
< 0.01, ***p < 0.001 and ****p < 0.0001 for comparison with the
medium, which was used as the control in all the tests.
Communication Nanoscale
Nanoscale This journal is © The Royal Society of Chemistry 2020
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
D
ec
em
be
r 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
/1
3/
20
20
 9
:4
5:
03
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
nulocyte-colony stimulating factor (G-CSF) mRNA, and thus,
enhancing its expression at the post transcriptional level.53
The activation of the canonical wnt signaling instead,
results in a proliferative eﬀect through the upregulation of
cyclin D1 protein expression.55
Next, the biocompatibility was also studied in primary
macrophages, which showed a higher sensitivity to the positive
nature of bare nanoparticles. As shown in Fig. 4, the nano-
particles without any surface modification drastically reduced
the viability of both M1- and M2-like macrophages, with
murine cells being the most sensitive. The cytotoxicity eﬀect
was both dose- and time-dependent. Also with primary macro-
phages, the surface functionalization and the loaded drugs
improved the cell biocompatibility of the nanoparticles.
2.4 Cell–nanoparticle interactions with macrophage cell lines
Macrophage cell lines, RAW 264.7 and KG-1, were first
screened to have preliminary indications on the behavior of
the cells in the presence of nanocarriers. Based on the above-
mentioned cytocompatibility results, the nanoparticle concen-
tration of 50 µg mL−1 was used in all uptake studies. The cell–
nanoparticle interaction was studied by flow cytometry ana-
lysis, by incubating the cells for 1 h with fluorescently labelled
nanoparticles, then washed and prepared for flow cytometry
analysis, which was performed by the detection of fluorescence
of AlexaFluor488®. Fig. 5 shows the median fluorescence inten-
sity (MFI) values for the two cell lines treated with PEGylated
and peptide-conjugated nanoparticles. MFI values are pro-
portional to the extent of the cell–nanoparticle interaction.
It is known that macrophages express ANP receptors.56
However, ANP significantly influences the uptake properties of
macrophages only after an appropriate incubation time
(18 h).56 Thus, in this work we did not study the eﬀect of ANP
on diﬀerent macrophages’ uptake profiles.
RAW 264.7 macrophages showed a preferential interaction
with Putre-AcDEX-PEG as compared with Putre-AcDEX-PEG-TT1-
ANP. It has been demonstrated that PEGylation improves the
“stealth” properties of nanoparticles, and thus, it is expected
that PEGylated nanoparticles interact less with cells.57 However,
the internalization rate of PEGylated nanoparticles in this par-
ticular case was faster. This can be explained considering that
the PEG attached to the particles had a low number of mono-
Fig. 4 Cytocompatibility of primary macrophages. Cell viability studies
on both human (A–D) and murine (E–H) M1-/M2-like macrophages.
Biocompatibility was assessed at both 24 (A, C, E, G) and 48 h (B, D, F,
H). Values are represented as mean ± s.d. (n = 3 biological replicates in
which each time 3 technical replicates have been used). A one-way
ANOVA followed by a Tukey–Kramer post hoc test was used for the stat-
istical analysis. The signiﬁcance levels of the diﬀerences were set at
probabilities of *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 for
comparison with the medium, which was used as the control in all the
tests.
Fig. 5 Quantitative uptake studies with macrophages cell lines. Uptake
studies have been carried out with both RAW 264.7 (A) and KG-1 (B) cell
lines incubated for 1 h with the nanoparticles. Values represent the MFI
± s.d. (n = 3 biological replicates in which each time 3 technical repli-
cates have been used). A one-way ANOVA followed by a Tukey–Kramer
post hoc test was used for the statistical analysis. The signiﬁcance levels
of the diﬀerences were set at probabilities of ***p < 0.01 for comparison
with Putre-AcDEX-PEG and Putre-AcDEX-PEG-TT1-ANP (both before
ﬂuorescence quenching with TB), and for Putre-AcDEX-PEG-TT1-ANP,
before and after ﬂuorescence quenching.
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mers per chain, and thus, it was expected to be internalized
faster compared to a PEG with a longer chain.58 In contrast to
flow cytometry results, confocal images in Fig. S1† showed that
particles conjugated with both peptides interacted more with
RAW macrophages as compared with the PEGylated nano-
systems. Nonetheless, confocal images are only representative of
part of the cell population and provide only a qualitative per-
spective on the interactions between cells and nanoparticles.
KG-1 cells, which are a human non-adherent macrophage
cell line, did not show any diﬀerence in the interaction
between the PEGylated nanosystems and the nanoparticles
functionalized with both ANP and TT1 peptides. It is hypoth-
esized that this could be due to the sedimentation of nano-
particles over time, excluding themselves from the interaction
with the cells.59
2.5 Polarization of human and murine monocytes
Monocytes were isolated and collected from human blood and
murine bone marrow. After collection, they were maturated
and then polarized into M1- and M2-like macrophages by
using diﬀerent cocktails of cytokines (Scheme S1†). In order to
confirm the impact of our polarization strategies, we assessed
the surface expression of a panel of M1 and M2 phenotypic
markers (Fig. S2 and S3†). For both MØ and LPS/IL-4 stimu-
lated macrophages of human origin, CD86 and CD206 were
used as M1 and M2 markers, respectively.60,61 Murine MØ
macrophages were recognized by the expression of F4/80 and
CD11b,62 whereas M1- and M2-like macrophages, were distin-
guished by the expression of CD206 and CD11c.63 Unstained
cells were used as controls. Before polarization with lipopoly-
saccharide (LPS), the majority of the human monocytes
matured with the granulocyte-macrophage colony-stimulating
factor (GM-CSF) were CD206+CD86− (Fig. S2A†). Treatment
with LPS shifted the expression of the markers towards an
increase of CD86 positive cells (Fig. S2B†), thus suggesting
that treatment with the cytokine was able to create a popu-
lation of M1-like macrophages. Similarly, monocytes treated
with the macrophage colony-stimulating factor (M-CSF), which
were double positive for CD206 and CD86 (Fig. S2C†), showed
a shift towards CD206+CD86− upon stimulation with interleu-
kine-4 (IL-4) (Fig. S2D†). Murine cells exhibited major plas-
ticity compared to human macrophages. Monocytes matured
with both GM-CSF and M-CSF were, respectively, CD11b+F4/
80− and double positive for F4/80 and CD11b (Fig. S3A†),
typical monocyte markers. Then, LPS stimulated MØ macro-
phages became CD11c+CD206− macrophages (Fig. S3B†),
whereas the cells treated with IL-4 were double positive
(Fig. S3D†). The cellular morphology also changed depending
on the cytokine treatment.
2.6 Cell–nanoparticle interactions with primary macrophages
Finally, the interactions between the nanoparticles and
primary macrophages were also assessed. Previous studies
already evaluated the eﬀect of macrophage polarization on
nanoparticle uptake, but they obtained contrasting results,
depending on the conditions used during the studies and,
most importantly, on the type on nanoparticle used.64–66
Ideally, for intravenous injectable nanosystems and the
“hitchhike” eﬀect to the infarcted heart by recruited macro-
phages to take place, the aim is to obtain a nanosystem that is
able to associate with the macrophages’ surface, without being
taken-up. To understand which type of macrophage was pre-
senting a higher nanoparticle–cell association rate versus
uptake, we evaluated the interactions between the hitchhiking
nanoparticles and the diﬀerentiated M1- and M2-like macro-
phages derived from both human and murine precursors.
Uptake studies were performed as previously done for continu-
ous cell lines.
From the results, we observed that Putre-AcDEX-PEG-TT1-
ANP nanoparticles generally interacted more with M2-like
macrophages compared to M1-like ones (Fig. 6). The nano-
particle–cell association vs. uptake ratio was higher for M2-like
macrophages in both human and murine cells, suggesting
that M2 macrophages can act as more eﬃcient carriers of
nanoparticles into the infarcted heart.
Considering these findings and the bi-phasic accumulation
of M1- and M2-like macrophages in the infarcted heart, the
particles presented here can reach the infarcted heart in an
Fig. 6 Quantitative cell uptake studies on primary M1- and M2-like
macrophages. Interactions between Putre-AcDEX nanoparticles and
cells were studied also on human (A, B) and murine (C, D) M1- and M2-
like macrophages. The results are represented as MFI values ± s.d. (n = 3
biological replicates in which each time 3 technical replicates have been
used). A one-way ANOVA followed by a Tukey–Kramer post hoc test was
used for the statistical analysis. The signiﬁcance levels of the diﬀerences
were set at probabilities of *p < 0.05 and ****p < 0.0001 for comparison
between Putre-AcDEX-PEG and the Putre-AcDEX-PEG-TT1-ANP (both
before ﬂuorescence quenching with TB), and for Putre-
AcDEX-PEG-TT1-ANP, before and after ﬂuorescence quenching.
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optimal timeframe. The final aim of the designed nanosystem
was to induce cardiomyocyte proliferation, restoring the loss of
beating cells and cardiac function after infarction. The loaded
drugs, C and S, were used for this aim, because it has been
shown in the literature that they have a synergic eﬀect in sti-
mulating cardiomyocyte proliferation.28 In order to be success-
ful in this strategy, we hypothesized that the first phase of
macrophage recruitment is needed to phagocytose dead cells
and debris, and to make space for the new regenerated
tissue.14 Thus, the ability to exploit the recruitment of M2-like
macrophages, suggests an increase of the chances for an
optimal tissue remodelling, because the proliferation of cardi-
omyocytes would contrast the formation of scar tissue.
The results were confirmed also by qualitative cell uptake
studies, using fluorescence confocal microscopy. Diﬀerent
macrophages were incubated with the nanoparticles for 1 h
and then fixed and stained. Finally, the samples were imaged
with an inverted confocal microscope. The images showed that
the nanoparticles conjugated with both the peptides interacted
more with the cells than the PEGylated ones. Moreover, in the
images particles looked green and not yellow, suggesting that
the nanoparticles were mainly associated with the surface of
the macrophages, and not taken-up (Fig. S4†).
Finally, we also studied the mechanism of internalization
of Putre-AcDEX-PEG-TT1-ANP nanoparticles. Since we
observed higher cell–NP association than cell uptake,
especially in M2-like macrophages, we also hypothesized
whether the nanoparticles were inducing frustrated endocyto-
sis. For this purpose, NP cell uptake mechanism studies were
carried out and quantified as percentage of positive events.
Primary macrophages were incubated with diﬀerent com-
pounds, in order to inhibit particular mechanisms of cell
internalization. Cytochalasin D (CytoD) was used at two
diﬀerent concentrations to study the micropinocytosis and the
role of actin in the endocytic process, because it is able to
depolarize actin filaments.67,68 Nocodazole was used as a
microtubule disruptor,69,70 in order to assess the influence of
microtubules on the nanoparticle internalization. Genistein is
an isoflavone used to inhibit caveoline-mediated endocytosis
as a result of its suppressive eﬀect on tyrosine kinases involved
in this type of internalization.70–72 Clathrin-mediated uptake
was inhibited by chlorpromazine, which interferes with cla-
thrin disassembly and receptor recycling to the plasma mem-
brane.73 Sodium azide was used to study whether the particles
were taken-up by active transport or not, because it interferes
with ATP production due to its ability to inhibit cytochrome c
oxidase.74,75 Adsorptive-mediated uptake was inhibited by pro-
tamine sulphate.76 All primary macrophages internalized the
nanoparticles preferentially by macropynocytosis, as shown in
Fig. 7.
Macrophages treated with Cyto D presented lower values of
percentage of positive events for nanoparticles taken-up as
compared, for example, to genistein and chlorpromazine,
which inhibit caveolin-mediated endocytosis and clathrin-
mediated uptake, respectively. Human derived macrophages
(Fig. 7A and B) had the lowest sensitivity to uptake inhibitors
compared to murine cells (Fig. 7C and D). Also, it was notable
that actin filaments, but not microtubules, were the cytoskele-
ton components involved in the uptake mechanism of the
Putre-AcDEX-PEG-TT1-ANP nanoparticles. All these findings
suggest the engagement of energy dependent pathways in the
endocytosis of the produced nanoparticles, justifying the high
association versus cell uptake observed in Fig. 6.
3. Conclusions
Herein, we report the design of a nanocarrier successfully
decorated with two diﬀerent peptides, TT1 and ANP, with
promising targeting ability towards infarcted heart tissue,
through the exploitation of macrophage recruitment. Putre-
AcDEX nanoparticles after surface modifications were biocom-
patible towards both macrophage cell lines and primary
macrophages of human and murine origin. Moreover, they
showed preferential association versus uptake with M2-like
macrophages (approximately 2-fold and 6-fold increase in
murine and human primary macrophages, respectively, com-
pared to M1-like), which makes them suitable candidates for
achieving the “hitchhike” eﬀect and target the infarcted heart
in the later stage of the inflammatory response. Overall, the
nanosystem developed here has the potential ability to exploit
the post-infarction recruitment of M2-like macrophages, to
Fig. 7 Study of the cell uptake mechanisms. Primary macrophages
were incubated with diﬀerent compounds, each one inhibiting a
diﬀerent mechanism of endocytosis, and then particles were added and
the cell uptake evaluated by ﬂow cytometry. Values represent the per-
centage of positive events ± s.d. (n = 3 biological replicates in which
each time 3 technical replicates have been used). A one-way ANOVA fol-
lowed by a Tukey–Kramer post hoc test was used for the statistical ana-
lysis. The signiﬁcance levels of the diﬀerences were set at probabilities
of *p < 0.1, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
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provide new targeting strategies in the field of nanomedicines
for heart disease treatment.
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